The Effects of Opioid Substitution Treatment and Highly Active Antiretroviral Therapy on the Cause-Specific Risk of Mortality among HIV-Positive People Who Inject Drugs

Clinical Infectious Diseases

Volumn 61, Issue 7, 2015, Pages 1157-1165

  Nosyk, Bohdan ^a,b   Min, Jeong E ^a   Evans, Elizabeth ^c   Li, Libo ^c   Liu, Lei ^d   Lima, Viviane D ^a,e   Wood, Evan ^a,e   Montaner, Julio S G ^a,e  

^a ST PAUL S HOSPITAL   (Canada)

^b SIMON FRASER UNIVERSITY   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

highly active antiretroviral therapy; HIV AIDS; injection drug users; mortality; opioid substitution treatment

Indexed keywords

ADULT; ARTICLE; CANADA; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MISCELLANEOUS NAMED GROUPS; MORTALITY; OPIATE SUBSTITUTION TREATMENT; PEOPLE WHO INJECT DRUG; PRIORITY JOURNAL; STANDARDIZED MORTALITY RATIO; ADOLESCENT; CHILD; COHORT ANALYSIS; COMPLICATION; HIV INFECTIONS; INFANT; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA; SUBSTANCE ABUSE; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; SUBSTANCE ABUSE, INTRAVENOUS; YOUNG ADULT;

EID: 84942163686     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ476     Document Type: Article

References (40)

1. Degenhardt L, Bucello C, Mathers B, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011; 106:32-51
2. Antiretroviral Therapy Cohort Collaboration; Zwahlen M, Harris R, May M, et al. Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries. Int J Epidemiol 2009; 38:1624-33
3. Palella FJ, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43:27-34
4. Mellors JM, Kingsley LA, Rinaldo CR, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995; 122:573-9
5. The HIV-CAUSAL Collaboration. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010; 28:321-9
6. Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat 2005; 28:321-9
7. Frishman WH, Del Vecchio A, Sanal S, Ismail A. Cardiovascular manifestations of substance abuse: part 2: alcohol, amphetamines, heroin, cannabis, and caffeine. Heart Dis 2003; 5:253-71
8. Herning RI, Better WE, Tate K, Umbricht A, Preston KL, Cadet JL. Methadone treatment induces attenuation of cerebrovascular deficits associated with the prolonged abuse of cocaine and heroin. Neuropsychopharmacology 2003; 28:562-8
9. Reece AS, Hulse GK. Lifetime opiate exposure as an independent and interactive cardiovascular risk factor in males: a cross-sectional clinical study. Vasc Health Risk Manag 2013; 9:551-61
10. Reece AS, Hulse GK. Opiate dependence as an independent and interactive risk factor for arterial stiffness and cardiovascular ageing-a longitudinal study in females. J Clin Med Res 2013; 5:356-67
11. Caplehorn JRM, Dalton MSYN, Cluff MC, Petrenas AM. Retention in methadone maintenance and heroin addicts' risk of death. Addiction 1994; 89:203-9
12. Degenhardt L, Randall D, Hall W, Law M, Butler T, Burns L. Mortality among clients of a state-wide opioid pharmacotherapy program over 20 years: risk factors and lives saved. Drug Alcohol Depend 2009; 105:9-15
13. Inturrisi CE, Colburn WA, Kaiko RF, Houde RW, Foley KM. Pharmacokinetics and pharmacodynamics of methadone in patients with chronic pain. Clin Pharmacol Ther 1987; 41:392-401
14. Ferrari A, Rosario Coccia CP, Bertolini A, Stemieri E. Methadone-metabolism, pharmacokinetics and interactions. Pharmacol Res 2004; 50:551-9
15. College of Physicians and Surgeons of British Columbia. Methadone Maintenance Program: Clinical Practice Guideline. Available at: https://www.cpsbc.ca/files/pdf/MMP-Clinical-Practice-Guideline.pdf. Accessed 26 June 2015
16. Stephenson DK, California Society of Addiction Medicine. Guideline for physicians working in California Opioid Treatment Programs. Available at: http://www.csam-asam.org/sites/default/files/CSAMOTP Guideline21Apr09.pdf. Accessed 26 June 2015
17. Roux P, Carrieri MP, Cohen J, et al. Retention in opioid substitution treatment: a major predictor of long-term virological success for HIV-infected injection drug users receiving antiretroviral treatment. Clin Infect Dis 2009; 49:1433-40
18. Nosyk B, Min J, Colley G, et al. The causal effect of opioid substitution treatment on highly active antiretroviral treatment adherence. Drug Alcohol Depend 2015; 146:e53-4
19. Nosyk B, Colley G, Yip B, et al. Application and validation of casefinding algorithms for identifying individuals with human immunodeficiency virus from administrative data in British Columbia, Canada. PLoS One 2013; 8:e54416
20. Heath K, Samji H, Nosyk B, et al. Cohort profile: seek and treat for the optimal prevention of HIV/AIDS in British Columbia (STOP HIV/ AIDS BC). Int J Epidemiol 2014; 43:1073-81
21. Nosyk B, MacNab YC, Sun H, et al. Proportional hazards frailty models for recurrent methadone maintenance treatment. Am J Epidemiol 2009; 170:783-92
22. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA 1996; 276:146-54
23. Thompson MA, Aberg JA, Hoy JF, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012; 308:387-402
24. Hogg RS, Heath K, Lima VD, et al. Regional disparities in the burden of HIV/AIDS in Canada. PLoS One 2012; 7:e47260
25. Schneeweiss S, Maclure M. Use of comorbidity scores for control of confounding in studies using administrative databases. Int J Epidemiol 2000; 29:891-8
26. Schumacher M, Wangler M, Wolkewitz M, Beyersmann J. Attributable mortality due to nosocomial infections: a simple and useful application of multistate models. Methods Inf Med 2007; 46:595-600
27. Allignol A, Schumacher M, Beyersmann J. Estimating summary functionals in multistate models with an application to hospital infection data. Comput Stat 2011; 26:181-97
28. Beyersmann J, Allignol A, Schumacher M. Competing risks and multistate models with R. New York: Springer, 2012
29. Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol 2009; 170:244-56
30. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000; 11:550-60
31. Hernan MA, Brumback B, Robins JM. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 2000; 11:561-70
32. Donahoe RM. Multiple ways that drug abuse might influence AIDS progression: clues from a monkey model. J Neuroimmunol 2004; 147:28-32
33. Baum MK, Rafie C, Lai S, Sales S, Page B, Campa A. Crack-cocaine use accelerates HIV disease progression in a cohort of HIV-positive drug users. J Acquir Immune Defic Syndr 2009; 50:93-9
34. Kapadia F, Vlahov D, Donahoe RM, Friedland G. The role of substance abuse in HIV disease progression: reconciling differences from laboratory and epidemiologic investigations. Clin Infect Dis 2005; 41:1027-34
35. Celentano D, Lucas G. Optimizing treatment outcomes in HIV-infected patients with substance abuse issues. Clin Infect Dis 2007; 45:S318-23
36. Banerjee A, StrazzaM, Wigdahl B, Pirrone V, Meucci O, Nonnemacher MR. Role of mu-opioids as cofactors in human immunodeficiency virus type 1 disease progression and neuropathogenesis. J Neurovirol 2011; 17:291-302
37. Cornish R, Macloed J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010; 341:c5475
38. Bekeart M, Vansteelandt S, Mertens K. Adjusting for time-varying confounding in the subdistribution analysis of a competing risk. Lifetime Data Anal 2010; 16:45-70
39. Kerr T, Werb D, DeBeck K, et al. Drug situation in Vancouver (UHRI Report): Urban Health Research Initiative, British Columbia Centre for Excellence in HIV/AIDS, 2009. Available at: http://www.cfenet.ubc.ca/sites/default/files/uploads/news/releases/war-on-drugs-failing-to-limit-drug-use.pdf. Accessed 26 June 2015
40. McCormick N, Lacaille D, Bhole V, Avina-Zubieta JA. Validity of myocardial infarction diagnoses in administrative databases: a systematic review. PLoS One 2014; 9:e92286